Telix Pharmaceuticals delivered solid second-quarter results that underscore its execution capabilities and market position in precision medicine. The company reported revenue of US$247 million, representing growth of 7% quarter-over-quarter and 21% year-over-year, with Precision Medicine segment leading the charge at US$202 million, up 30% year-over-year. This performance trajectory positions Telix to exceed US$1 billion in full-year FY 2026 revenue, a milestone that validates the commercial potential of its core PSMA imaging platform while the company simultaneously progresses its therapeutic pipeline.
The underlying growth dynamics merit investor attention. U.S. dose volumes expanded 7% during the quarter, driven principally by rising demand for Gozellix and strength across the PSMA imaging portfolio. This growth occurred against a backdrop of supply chain resilience and clinical differentiation, two factors that provide competitive moats in a market increasingly focused on precision diagnostics. The company’s two-product PSMA strategy appears to be resonating with clinicians and patients, suggesting that Telix has carved out genuine clinical value beyond simple market share capture.
Beyond revenue, Telix marked meaningful clinical and regulatory progress that could reshape its longer-term growth profile. The FDA confirmed that safety data from the first part of the ProstACT Global Phase 3 trial for TLX591-Tx, Telix’s lead prostate cancer therapeutic, supports advancement to Part 2 in the United States. Regulatory momentum matters in oncology, where each milestone de-risks the path to commercial launch. The company also disclosed that its BiPASS study of Illuccix and Gozellix for pre-biopsy prostate cancer diagnosis is nearing enrollment completion, a step forward for expanding the addressable market within its existing product suite.
The Regeneron collaboration represents a validation event that extends beyond capital. The strategic partnership to jointly develop and commercialize next-generation radiopharmaceutical therapies, initially targeting lung cancer, signals that Telix’s radiopharmaceutical platform has attracted a blue-chip partner with meaningful commercial and R&D resources. The US$40 million non-refundable payment from Regeneron sits alongside Telix’s strong operational performance to fund an expanded R&D envelope of US$230 million to US$270 million for FY 2026. This reinvestment demonstrates management confidence in pipeline acceleration.
Investors should monitor several catalysts ahead. Progression of TLX591-Tx through Phase 2 in the United States will be closely watched by the market, as will enrollment completion and interim readouts from BiPASS. Commercial traction in the existing PSMA portfolio remains a key barometer of Telix’s ability to sustain growth and defend market position. The company indicated it is tracking in line with the upper end of FY 2026 revenue guidance, a statement that warrants close attention to quarterly progression through year-end. This announcement is price sensitive and has been flagged as material by the ASX.
View the full ASX announcement (PDF)
About TELIX Pharmaceuticals Limited (ASX: TLX)
TELIX Pharmaceuticals Limited is a commercial-stage biopharmaceutical company that develops and commercializes therapeutic and diagnostic radiopharmaceuticals for oncology and other serious diseases. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions, focusing on targeted radiation therapies for various cancer indications. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
